Source link : https://www.newshealth.biz/health-news/dupilumab-safe-effective-over-5-years-in-moderate-severe-ad/
TOPLINE: Over 5 years, dupilumab demonstrated acceptable safety and sustained efficacy, with significant improvements in the signs and symptoms of AD, in the treatment of moderate to severe atopic dermatitis (AD). METHODOLOGY: The phase 3 multinational LIBERTY AD open-label extension study evaluated the safety and efficacy of dupilumab in 2677 adults with moderate to severe […]
Author : News Health
Publish date : 2024-07-10 15:00:00
Copyright for syndicated content belongs to the linked Source.